Sage Journals: Discover world-class research

Abstract

Transforming growth factor-β1 (TGF-β1) plays a central role in the response of the brain to different types of injury. Increased TGF-β1 has been found in the central nervous system of patients with acute or chronic disorders such as stroke or Alzheimer disease. To further define the molecular targets of TGF-β1 in cerebral tissues, a selection of high-density cDNA arrays was used to characterize the mRNA expression profile of 7,000 genes in transgenic mice overexpressing TGF-β1 from astrocytes as compared with the wild-type line. Selected findings were further evaluated by reverse transcription-polymerase chain reactions from independent transgenic and wild-type mice. Furthermore, the expression pattern of seven selected genes such as Delta-1, CRADD, PRSC-1, PAI-1, Apo-1/Fas, CTS-B, and TβR-II were confirmed in either cultured cortical neurons or astrocytes following TGF-β1 treatment. The authors' observations enlarge the repertoire of known TGF-β1–modulated genes and their possible involvement in neurodegenerative processes.

Keywords

cDNA macroarray RT-PCR Gene expression TGF-β1 transgenic mice

Many diseases of the central nervous system are initiated by a large cascade of events that lead to neuronal cell death, which occurs through necrotic and apoptotic mechanisms. Although considerable interest exists in developing effective methods to modulate these two fatal pathways, most of the drugs tested so far have shown either no significant protective activity or sufficient harmful side effects so as to be inappropriate for use in patients (del Zoppo et al., 1997). In contrast, the use of neurotrophic factors could represent an interesting alternative therapeutic strategy against both acute and chronic brain neurodegenerative processes. Based on these observations, there is considerable interest to further understand the molecular mechanisms through which cytokines may modulate many neuropathologic processes.

Among these cytokines, transforming growth factor-β1 (TGF-β1) is a prototype of various multifunctional cytokines and has been previously characterized as an injury-related molecule in both rodents and man (Flanders et al., 1998; Krieglstein and Krieglstein, 1997). Transforming growth factor-β has been characterized for its pleiotropic activity and its ability to control cellular functions that underlie embryonic development and tissue homeostasis. The basic signaling machinery consists of two serine/threonine kinase receptors and a family of transcription factors: the Smad family (Piek et al., 1999; Massagué, 2000). Such complexes recognizing the TGF-β–inducible element CAGAC contribute to the transcriptional activity of this cytokine. Smad proteins are often found to be associated with other transcription factors such as CBP/p300 (Massagué and Wotton, 2000), Sp1 (Moustakas and Kardassis, 1998; Brodin et al., 2000; Pardali et al., 2000; Feng et al., 2000; Datta et al., 2000), and AP-1 (i.e., c-fos/c-jun complex) (Zhang et al., 1998; Wong et al., 1999; Liberati et al., 1999). However, the diversity of effects displayed by this simple system remains largely unknown.

In vivo, several studies have reported a marked increase in TGF-β expression after an ischemic insult to the brain (Wiessne et al., 1993; Lehrmann et al., 1995; Krupinski et al., 1996). In vitro, we have demonstrated that TGF-β1 exerts a neuroprotective activity against NMDA-induced neuronal death via an upregulation of the type I plasminogen activator inhibitor (PAI-1) in astrocytes (Docagne et al., 1999). PAI-1 is markedly induced by TGF-β1 in many cell models (Matrisian and Hogan, 1990; Westerhausen et al., 1991; McCaffrey, 2000), and multiple TGF-β–responsive elements have been described in its promoter (Dennler et al., 1998). It has also been shown that an overproduction of TGF-β1 is associated with the pathology of Alzheimer disease and that 18-month-old transgenic mice overexpressing TGF-β1 in astrocytes elicit enhanced amyloid-β (Aβ) deposition in cerebral blood vessels and meninges (Wyss-Coray et al., 1997). In addition to this proamyloidogenic role of TGF-β1, the same group demonstrated, in a recent report, that 12- to 15-month-old double transgenic mice expressing TGF-β1 and human amyloid-β precursor protein (hAPP) display reduced numbers of parenchymal plaques (Wyss-Coray et al., 2001). Despite unknown Aβ-promoting mechanisms in these transgenic models, these data suggest that TGF-β1 is an important regulator of Aβ deposition in vivo.

Many genes have been reported to be modulated after TGF-β exposure, such as PAI-1 (Westerhausen et al., 1991; Keeton et al., 1991; Riccio et al., 1992), TGF-β1 (Van Obberghen-Schilling et al., 1988; Kim et al., 1989), the cyclin-dependent kinases inhibitors p21 and p15 (Elbendary et al., 1994; Li et al., 1995; Datto et al., 1997), fibronectin (Ignotz et al., 1987) and collagen a2(I) (Inagaki et al., 1994). Based on the pleiotropic activities of this cytokine, these genes represent probably a minor fraction of all genes induced or repressed following a TGF-β signal. Identification of these genes and the ultimate characterization of their functions are crucial to understand the pathology of brain diseases in which TGF-β is believed to play a critical role.

To further investigate the molecular events through which TGF-β1 influences the evolution of threatened brain tissue, we used cDNA arrays to analyze the expression pattern of 7,104 genes from brains of both wild-type (WT) and transgenic (Tg) mice overexpressing TGF-β1 in astrocytes. These mice express a bioactive form of TGF-β1 by astrocytes and were previously characterized and used as a transgenic model of amyloid deposition (Wyss-Coray et al., 1995, 1997, 2001). Some selected TGF-β1–regulated genes potentially related in neurodegenerative diseases were then further analyzed in TGF-β1–treated cultures of cortical neurons and astrocytes.

MATERIALS AND METHODS

The reverse transcriptase system kit and the polymerase chain reaction kit were obtained from Promega (Paris, France). Dulbecco's Modified Eagle's medium (DMEM), cytosine arabinoside, horse serum and fetal bovine serum, poly-d-lysine, and laminin were obtained from Sigma Chemical Co. (L'Isle D'Abeau, France), as were all other chemicals used. Human recombinant TGF-β1 was purchased from R&D Systems Europe (Oxford, U.K.).

Cell cultures

Cortical cultures of astrocytes

Cortical cultures of astrocytes were prepared from 1- to 3-day-old postnatal mice (Rose et al., 1993). Cerebral cortices were microdissected and incubated in DMEM containing 2 mmol/L glutamine supplemented with 10% fetal bovine (FCS) and 10% horse serum (HS). Cultures were kept at 37°C in a humidified 5% CO₂-containing atmosphere. After 3 days in vitro (DIV), astrocytes were vigorously washed 3 times with phosphate-buffered saline, and this process was repeated every 3 days to prevent contamination of cell cultures by microglia. Purity of culture has been estimated under our conditions, where 99% of cells were glial fibrillary acidic protein (GFAP)-positive. Experiments were performed on confluent cultured cortical astrocytes after 10 DIV.

Cultures of cortical neurons

Cultures of cortical neurons were prepared from 14- to 15-day-old mice embryos as previously described (Rose et al., 1993), plated in 2-cm² dishes previously coated with poly-d-lysine and 0.5 mg/mL laminin. Cultures were performed in DMEM supplemented with 2 mmol/L glutamine in the presence of 5% FCS and 5% HS. After 3 DIV, neurons were treated with 10 μmol/L cytosine arabinoside to inhibit the proliferation of astrocytes. Experiments were realized on pure neuronal cultures (>98% of microtubule-associated protein 2 immunoreactive cells) after 12 to 14 DIV.

Transgenic mice

To determine TGF-β1-related cerebral gene expression, we used brains from Tg mice overexpressing TGF-β1 in astrocytes from the GFAP promoter (line T65) generated by Lennart Mucke's laboratory similarly to the previously described low-expressing GFAP-TGF-β1 transgenic lines, T64 and T115 (Wyss-Coray et al., 1995). These mice express large amounts of the transgene associated with enhanced expression of endogenous TGF-β1 as determined either by RT-PCR or by immunoblotting (data not shown).

Gene expression profiling

Human brain cDNA arrays

Human brain cDNA arrays were prepared with a set of 7,104 cDNA clones selected from a normalized infant brain library (library 1NIB, [Soares et al., 1994]). The 3' and/or 5' ends of these 7,104 cDNA clones have been previously sequenced (Houlgatte et al., 1995). The sequences, registered in Genbank (http://www.ncbi.nlm.nih.gov/Genbank), have been compared with those in public databases, permitting a tentative identification of the corresponding gene transcripts. Each insert was amplified by PCR with vector-specific primers and spotted at medium density (25 PCR products/cm²) onto nylon membranes (Hybond-N+, Amersham Pharmacia Biotech U.K., Ltd., Little Chalfont, Buckinghamshire, U.K.) by a robot (Flexis, Perkin Elmer), as previously described (Piétu et al., 1996; Decraene et al., 1999). A set of 137 known genes and 84 negative and positive controls were added to the filters. The entire collection was spotted on a set of 4 filters.

Preparation and labeling of complex cDNA targets

Preparation and labeling of complex cDNA targets were based on [α-³³P]-labeled complex cDNA targets which were synthesized by reverse transcription of 500-ng poly(A)+ brain mRNA extracted from Tg and WT lines (3 animals for each group). The reaction was performed with the SuperScript Preamplification System (Invitrogen, SARL, Cergy Pontoise, France) in the presence of 50-μCi [α-³³P]dATP, 3,000 Ci/mmol (Amersham Pharmacia Biotech) as previously described (Decraene et al., 1999).

Hybridization and signal quantitation

Hybridization and signal quantitation were performed under nonstringent conditions to allow optimal hybridization between the human cDNA probes and the mouse cDNA targets. Membranes were prehybridized at 68°C for 30 minutes in an ExpressHyb solution (Clontech, Palo Alto, CA, U.S.A.), hybridized for 2 hours in the same solution to which the radiolabeled complex cDNA target was added, then washed twice for 30 minutes at 25°C in standard saline citrate (SSC)/0.1% sodium dodecyl sulfate (SDS), and twice for 30 minutes at 25°C in SSC/0.1% SDS. The washed filters were exposed to phosphorus screens (Amersham Biosciences, Sunnyvale, CA, U.S.A.) for 16 hours.

Under such conditions, among the 7,104 cDNA clones, 4,651 and 4,525 clones were significantly detected in WT or Tg brain tissues, respectively. Differential gene expression was determined by calculating the ratio of the normalized hybridization signal intensity for each clone obtained with the WT brain cDNA target to that obtained with the Tg brain cDNA target. Genes were considered to be differentially expressed in Tg brain compared with WT brain if the ratio between the corresponding hybridization intensity values was greater than 1.67 (upregulated clones) or less than 0.60 (downregulated clones), the limits of confidence for the method. Applying these selection criteria, the vast majority of genes (95%) showed relatively little change in mRNA expression levels.

Image acquisition was performed on a PhosphorImager (Amersham Biosciences). Identification and quantitation of the spots were performed by the XdotsReader software (Cose, Le Bourget, France). After subtraction of the background, normalized intensity values for each clone in each experimental condition were determined as the average of the intensity of the hybridization signal for one clone divided by the intensity obtained for all clones deposited on the filters. Duplicate filters were hybridized with an initial preparation of each target; the entire set of hybridization was then repeated with novel target preparations, so that for each clone/target combination, four hybridization data points were collected. The four values were compared and validated if at least three of the four values were similar (SD < 25%). The final value assigned to each clone was the average of the validated values.

Semiquantitative reverse transcriptase-polymerase chain reaction

Total RNAs (Figs. 2 to 4) or polyadenylated mRNAs (Fig. 1), as indicated in the Figures legends, were prepared from cerebral cortex, cultured neurons, and astrocytes by either the phenol/chloroform extraction method using the RNAXEL extraction kit (Eurobio, Paris, France) or the RNAeasy system (Qiagen S.A., Courtaboeuf, France). One microgram of total RNA was transcribed into cDNA via poly-dT oligonucleotides. An aliquot of the cDNAs so produced was amplified using sense and antisense primers for each selected gene and β-actin respectively. For semiquantitative experiments, an aliquot of cDNA libraries was amplified by PCR with specific oligonucleotides (Table 1) or for β-actin (25 cycles of PCR were chosen, corresponding to the 50%-of-the-saturation curve of the PCR products). For each chosen gene, PCR cycles indicated in Table 1 correspond to the 50%-of-the-saturation curve of the PCR product. Amplified products were then separated by agarose gel electrophoresis and visualized by ethidium bromide staining. PCR experiments were performed only if the expression pattern obtained for the housekeeping gene, β-actin, failed to show any significant modification between different samples. We also verified that quantitation of ethidium bromide-stained PCR bands was accurate. To this end, we amplified β-actin mRNA by using increasing amounts of cDNA and found a direct correlation between data obtained from densitometry analysis and amounts of cDNA used.

Fig. 1.

Characterization of GFAP-TGF-β1 transgenic mice. Polyadenylated mRNAs encoding for either the transgene, transcripts for TGF-β1 and type I plasminogen activator inhibitor (PAI-1) in addition to the housekeeping gene β-actin, harvested from cortices of both transgenic (Tg) and wild-type (WT) mice, were reverse transcribed as described in the methods section and amplified by using corresponding oligonucleotides prior to agarose gel electrophoresis and ethidium bromide staining. GFAP, glial fibrillary acidic protein; TGF-β1, transforming growth factor-β1.

Fig. 2.

Reverse transcription-polymerase chain reaction (RT-PCR) analysis of cDNA array-selected genes from the brains of both wild-type (WT) and GFAP-TGF-β transgenic (Tg) mice. (A) The agarose gel electrophoreses presented are representative experiments of three independent RT-PCR. Shaded and empty arrows illustrate up- and down-regulation respectively. Arrows at the left and at the right of the figure indicate the score obtained by cDNA array and RT-PCR experiments, respectively. (B) The levels of the PCR products for Delta-1, PRSC-1, CTS-B, CRADD, Apo-1/Fas, TβSRII, PAI-1, and β-actin mRNA were estimated by densitometric analyses and the means ± SD of the three animals analyzed plotted as a percentage of WT. Light and dark bars (means ± SD) represent WT and Tg mice, respectively. GFAP, glial fibrillary acidic protein; TGF-β1, transforming growth factor-β1. Statistical analysis was performed by using a Bonferroni-Dunn's test followed by ANOVA (N = 3, n = 3, * P < 0.04).

Fig. 4.

Reverse transcription-polymerase chain reaction (RT-PCR) analysis of cDNA array-selected genes from primary cultures of cortical neurons following exposure to transforming growth factor-β1 (TGF-β1). (A) Gene expression in control untreated neurons (C) and in neurons exposed to a 12-hour TGF-β1 exposure (T). Agarose gel electrophoreses are representative data of three independent experiments. Dark and empty arrows illustrate upregulation and downregulation, respectively. Arrows at the left and at the right of the figure indicate the score obtained by cDNA array and RT-PCR experiments, respectively. (B) The levels of the PCR products for Delta-1, PRSC-1, CTS-B, CRADD, Apo-1/Fas, TβRII, PAI-1, and β-actin mRNA were estimated by densitometric analyses and the means ± SD of the three independent experiments plotted as a percent of controls. Light and dark bars (means ± SD) represent untreated and TGF-β1-exposed cultures of pure cortical neurons (1 ng/mL for 12 hours in 0% FCS-containing medium), respectively. Statistical analysis was performed by using a Bonferroni-Dunn's test followed by ANOVA (N = 3, n = 3, *P < 0.04).

Table 1.

Oligonucleotides and amplification conditions used for reverse transcription-polymerase chain reaction analysis

Gene	Oligonucleotide sequence sense antisense	Product size (bps)	Annealing temperature	No. of PCR cycles
Delta-1	5' CTG AAC TAC TGC ACA CAC CAT AAG C 3'	397	58	40
	5' CAC ACT TGG CAC CAT TAG AAC AG 3'
PRSC-1	5' GGA GAG TCA GGA GCA ACC TG 3'	500	58	40
	5' TCC TAG GCA CGA CGG CAG CAT C 3'
CTS-B	5' CAG GGVC TCC TGC GGC TCT TG 3'	613	58	35
	5' CAC CCC AGT CAA GGT TCC AAG 3'
CRADD	5' GGT ACT CCG CTC CCT GCG TC 3'	464	58	40
	5' CCA CCA CCT GCG AAT GCA CG 3'
APO1/Fas	5' GTG TTC GCT GCG CCT C 3'	479	58	35
	5' GGT TCT GCG ACA TTC GGC 3'
TβRII	5' CCG GGA TCC CGC TTT GCT GAG GTC TAT AAG GC 3'	394	55	40
	5' CCG GGA TCC GAT ATT GGA GCT CTT GAG GTC CCT 3'
PAI-1	5' ATG AGA TCA GTA CTG CGG ATG CCA TCT 3'	322	55	35
	5' GCA CAG AGA CGG TGC TGC CAT CAG ACT 3'
β-Actin	5' GTG GG CGC TCT AGG CAC AA 3'	539	58	25
	5' CTC TTT GAT GTC ACG CAC GAT TTC 3'

Tabulation of sense and antisense primers that were used to detect the mRNA expression of the indicated genes by reverse transcription-polymerase chain reaction (see Table 2 for the full names of the genes and their accession numbers).

bps, base pairs.

Table 2.

Transforming growth factor-β1–regulated genes identified by cDNA array and selected for their link with neurodegenerative disorders

GeneBank access no.	Gene	Function	Ratio
*D49396	APO1/Fas receptor	Fas-ligand-induced apoptosis	0.54
*NM007452	Mouse anti-oxydant protein 1 (Aop1)
*M28723	Mouse housekeeping-type protein (MER5)
AF 211935	Human/mouse peroxiredoxin III (Prx3)
	Highly similar to ADP-ribosilation factor-6 (ARF-6)	Membrane trafficking, protusion formation	0.56
*NM011175	Putative cysteine protease PRSC-1	Unknown	0.68
*D55696	Mouse cysteine protease
AF012872	Phosphatidylinositol 4-kinase α	Biosynthesis of phosphatidylinositol-4,5-biphosphate	1.41
AB011161	KIAA0589 protein (FK-506–binding protein 3)	Immunosuppression	1.69
AF005418	Cytochrome P450/retinoic acid hydroxylase	Retinoic acid biosynthesis	1.69
NM007811	Mouse cytochrome P450
NM002111	Huntingtin	Unknown	1.7
AF211943	WW domain-containing oxidoreductase (WWOX)	Steroid metabolism	1.71
AF227527	FOR II protein
AF227526	FOR I protein
*NM003805	Caspase and RIP adapter with death domain (CRADD)
		Regulation of apoptosis mediated by caspases	1.72
*NM0099540	Mouse CRADD/RAIDD Weakly similar to ORF2		1.72
AF088219	CC chemokine gene cluster
AF044083	Major histocompatibility locus class III region
U44954	NMDA receptor glutamate-binding chain (hnrgw)	Unknown	1.74
AF182040	Mouse glutamate-binding protein LAG	Unknown
AF001433	Putative zinc finger protein Requiem (REQ)	Apoptosis-associated gene	1.75
NM011262	Mouse Requiem protein
X67336	Peripheral-type benzodiazepine receptor type II (PBRII)	1.75
NM007007	Pre-mRNA cleavage factor Im (kd) (CFIM)
*AF222310	Delta-1	Notch ligand; cell differentation and proliferation	1.76
*NM005618	Mouse Delta-1
*J 02685	Plasminogen activator inhibitor (PAI) Mouse plasminogen activator inhibitor	Physiologic inhibitor of plasminogen activators	1.76
*AF058888	Notch-3	Receptor of Delta; cell differentiation and proliferation	1.77
*X74760	Mouse Notch-3
NM001471	γ-Aminobutyric acid (GABA) B receptor, 1	Modulation of synaptic transmission	1.77
NM000234	Ligase I DNA ATP-dependent	DNA repair and recombination	1.78
NM010715	Mouse ligase I DNA ATP-dependent
AF000974	Zyxn-related protein (ZRP-1)	Interaction with cytosolic protein tyrosine kinase phosphatase hPTP1E	1.78
AJ001902	Thyroid receptor-interacting protein 6 (TRIP6)
AF116823	Mouse thyroid hormone receptor-interacting protein 6 (Trip6)
NM000153	Galactocerebrosidase	Degradation of myelinic galactolipids	1.83
AF251039	Putative zinc finger protein Hairless (hr)	Antagonist of the Notch signaling pathway; cell differentiation and proliferation	1.84
*XM002599	DNA J protein homolog (HSJ1)	Neuronal chaperone; intracellular protein trafficking and folding	1.86
*L16510	Cathepsin B (CTSB)	Lysosomal cysteine protease; induces apoptosis	1.9
*NM007798	Mouse cathepsin B
AX017254	α-2-Macroglobulin receptor-associated protein (a2MRAP/HBP-44)	Inhibitor of LDL receptor family	1.92
D00622	Mouse HBP-44
AF092905	Phosphatase I catalytic subunit	Dephosphorylation	1.97
M27073	Mouse protein phosphatase type 1
NM004648	SH2-domain-bearing protein tyrosin phosphatase substrate-1 (SHPS-1)	Growth factor– and cell adhesion-induced cell signaling	2.03
*D50683	TGF-β receptor type II	Receptor of TGF-βs; proliferation, neuroprotection	2.06
NM001660	ADP-ribosylation factor 4 (ARF4)	Vesicular trafficking, activator of phospholipase D	2.11
NM007479	Mouse ARF4

Genes selected from a Medline analysis that shows a high score for both keywords (“TGF-β” and “brain”) are presented with their cDNA probe access number, their full names and standard abbreviation, their GeneBank access number, their function, and the normalized ratio, obtained by cDNA array.

Genes selected for further reverse transcription-polymerase chain reaction analyses.

TGF-β, transforming growth factor-β.

RESULTS

Identification of brain-derived genes differentially expressed between wild-type and glial fibrillary acidic protein-transforming growth factor-β1 transgenic mice

Mice used for this study were previously characterized as expressing the GFAP-TGF-β1 transgene (Wyss-Coray et al., 1995) and their corresponding WT line. In the Tg line, transgene-derived bioactive TGF-β1 is produced by astrocytes from birth based on a transcriptional control by the modified astrocytic GFAP promoter. To assess the transgenic properties of our murine line, we performed semiquantitative RT-PCR for TGF-β1 transgene, endogenous TGF-β1 mRNA, and a gene previously characterized as inducible by TGF-β1, PAI-1 (Westerhausen et al., 1991; Dennler et al., 1998) from both Tg and WT lines (Fig. 1). All our PCR reactions showed the same level of expression of chosen housekeeping gene (β-actin). Each set of oligonucleotides gave products of the expected size for the GFAP-TGF-β1 transgene and for PAI-1. Specificity of PCR products has been previously demonstrated by sequencing (Wyss-Coray et al., 1997; Docagne et al., 1999). Assessment of cerebral TGF-β1 and PAI-1 confirmed the robust association between TGF-β1 expression and cerebral production of PAI-1 in Tg animals when compared with their non-Tg controls. These data indicate that GFAP-TGF-β1 Tg mice are an appropriate model to determine the pattern of genes that are under the control of TGF-β1 in cerebral tissues.

We used the cDNA arrays corresponding to 7,104 cDNA clones to identify genes differentially expressed from the brain tissues of WT mice when compared with Tg mice expressing TGF-β1. Spots with variable intensities were observed. The mean differences in hybridization signal intensity reflect a difference in the steady-state level of transcription. To avoid a misinterpretation due to lowly expressed genes, only those clones that gave a hybridization signal two-fold greater than background were taken into consideration. Under such conditions, there were 239 genes that displayed a modulated expression; 174 were identified as upregulated in Tg versus WT mice, whereas 65 were downregulated. The results of expression profiling are detailed in Table A and Table B at the web site on the following address: http://www.unicaen.fr/unicaen/ufr/medecine/neurosciences/cdnatgfbeta1.html.

Partial 5' and 3' sequences of the 239 clones were compared with all the sequences present in the UniGene database (http://www.ncbi.nlm.nih.gov/UniGene/). From the 174 genes found to be upregulated in Tg (Table A on the web site), a sequence homology search revealed that 59 of them correspond to sequences that are related to human genes that encode proteins with a known function. Thirty-seven clones were found to be similar to genes encoding proteins without known function, and 34 clones corresponded to poorly characterized genes that demonstrated either no or a weak similarity with sequences registered in the databases.

From the 65 genes found to be downregulated in Tg (Table B on the web site), 23 corresponded to human genes encoding proteins with a known function. In addition, 12 clones were found to be identical with sequences of unknown function. Finally, 12 clones corresponded to poorly characterized genes with no similarity with the sequences found in the databases.

Accordingly, 28 clones corresponding to 37 differentially expressed genes encode proteins that have been reported to play a role in the physiopathology of various CNS disease states (Table 2). Among these genes, some of them are directly related with the TGF-β1 signaling pathway (TGF-β type II receptor, the FK506-binding protein, and PAI-1), others are associated with cell death in both necrotic and apoptotic cascades (CRADD, Apo-1/Fas, requiem HREQ), while yet others are characteristic of neurologic disorders (Delta-1, Notch 3, Huntingtin, cathepsin B, putative cysteine protease: PRSC-1). Although the majority of these genes are upregulated in Tg mice when compared with the WT line, Apo-1/Fas and the cysteine protease PRSC-1 are downregulated with increased TGF-β1 expression.

To confirm the data obtained with the cDNA arrays, we assessed the expression of a set of seven genes by RT-PCR from WT and Tg mice. These seven genes were chosen for their involvement in neurodegenerative diseases including acute (cerebral ischemia, trauma) and progressive (CADASIL [cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy], Alzheimer disease) disorders (Peter and Krammer, 1998; Pinkoski and Green, 1999; Schneider and Tschopp, 2000; Vivien and Buisson, 2000; Mattson, 2000; Hughes and Olson, 2001). Oligonucleotides primers were designed for several genes, such as Delta-1, CRADD, PRSC-1, PAI-1, Apo-1/Fas, CTS-B, and TβR-II (Table 1). RT-PCR experiments were performed on total mRNA harvested from three WT and three Tg mice. For the seven genes, mRNA expression was estimated by densitometric analysis of corresponding PCR products following ethidium bromide staining of three independent experiments performed from three animals (N = 3; n = 3). All expression patterns matched with the data obtained from the cDNA array analysis (Figs. 2A and 2B). Based on these results, we are able to confirm the predictive power of the cDNA array screening experiments in our system.

Expression pattern of differentially expressed genes in cultured cortical neurons and astrocytes after exposure to transforming growth factor-β1

To further investigate the expression pattern of these seven selected genes, we have performed semiquantitative RT-PCR experiments from primary cultures of cortical astrocytes and neurons exposed to treatment with TGF-β1 (1 ng/mL) for 12 hours. In these models, we have studied the expression of the mRNA encoding for Delta-1, CRADD, PRSC-1, PAI-1, Apo-1/Fas, CTS-B, and TβR-II (see Table 1). Transcriptional expression was assessed by the densitometric analysis of corresponding PCR products following ethidium bromide staining in three independent experiments (n = 3). We showed that the mRNAs of all selected genes were expressed in cultured astrocytes. As shown in Fig. 3, the addition of TGF-β1 promoted the transcription of the mRNAs encoding for Delta-1, CRADD, PAI-1, and CTS-B in cultured astrocytes as illustrated by the cDNA array analysis. Similarly, TGF-β1 reduced the expression of the mRNA for PRSC-1 and Apo-1/Fas in cultured astrocytes, whereas the expression of TβR-II mRNA was not affected.

Fig. 3.

Reverse transcription-polymerase chain reaction (RT-PCR) analysis of cDNA array-selected genes from primary cultures of cortical astrocytes following exposure to transforming growth factor-β1 (TGF-β1). (A) Gene expression in control untreated astrocytes (C) and in astrocytes exposed to a 12-hour TGF-β1 exposure (T). Agarose gel electrophoreses are representative data of three independent experiments. Dark and empty arrows illustrate upregulation and downregulation, respectively. Arrows at the left and at the right of the figure indicate the score obtained by cDNA array and RT-PCR experiments, respectively. (B) The levels of the PCR products for Delta-1, PRSC-1, CTS-B, CRADD, Apo-1/Fas, TβSRII, PAI-1, and β-actin mRNA were estimated by densitometric analysis and the means ± SD of the three independent experiments plotted as a percentage of controls. Light and dark bars (means ± SD) represent untreated and TGF-β1–exposed cultures of cortical astrocytes (1 ng/mL for 12 hours in 0% FCS-containing medium), respectively. Statistical analyses was performed by using a Bonferroni-Dunn's test followed by ANOVA (N = 3, n = 3, *P < 0.04).

In contrast, the application of TGF-β1 to cultured neurons failed to influence the expression pattern of most of the genes tested, such as Delta-1, CRADD, PAI-1, Apo-1/Fas and CTS-B (Figs. 4A and 4B). However, the expression of the mRNA for PRSC-1 was reduced. As previously shown (Docagne et al., 1999), cultured cortical neurons do not exhibit mRNA that encodes for PAI-1. It is interesting to note that, although TGF-β1 did not influence the expression pattern of the mRNA for TβR-II in cultured astrocytes, it clearly induced an overexpression of the mRNA for TβR-II in cultured neurons.

DISCUSSION

Based on the results obtained in this study, we suggest that brain-derived TGF-β1 within the CNS would be a key element in the physiopathology of a number of disease processes. Our data evidence that TGF-β1 modulates the transcriptional activity of genes directly involved in the apoptotic cascade, such as Apo-1/Fas, CRADD, and Requiem. Apo-1/Fas, also called the CD95 receptor or tumor necrosis factor-related receptor (TNF-α R), is critically involved in the induction of apoptosis (Peter and Krammer, 1998; Pinkoski and Green, 1999; Schneider and Tschopp, 2000). An ischemic insult to the brain evokes a cellular stress, which involves the expression and the activation of the Apo-1/Fas receptor pathway (Matsuyama et al., 1994, 1995; Martin-Villalba et al., 1999; Rosenbaum et al., 2000). Fas-induced apoptosis involves the recruitment of procaspase-8 (cysteine aspartate-specific proteinase) through death domain-containing adaptor/signaling proteins such as CRADD or FADD to form the death-inducing signaling complex (DISC) (Boldin et al., 1996; Muzio et al., 1998). Accordingly, CRADD could play a role in the regulation of apoptosis in mammalian cells. The DISC formation leads to the proteolytic activation of procaspase-8 into caspase-8, which is released finally from the DISC into the cytoplasm (Muzio et al., 1996). Active caspase-8 cleaves various proteins including procaspase-3, and results in its activation and the completion of the cell death program (Stennicke et al., 1998). Interestingly, although the function of TGF-β1 is not so far characterized, we have shown that the overexpression of TGF-β1 in brain tissue leads to the activation of the transcription of a putative cysteine protease, PRSC-1.

The overexpression of PAI-1 observed in the GFAP-TGF-β1 transgenic mice is instructive. We have recently demonstrated that an upregulation of the expression of this serine protease inhibitor (PAI-1) in astrocytes mediates the neuroprotective activity of TGF-β1 against a variety of excitotoxic challenges in cultures cortical neurons (Wiessner et al., 1993; Buisson et al., 1998). These data are reinforced by the demonstration that blocking TGF-β signaling in cerebral tissue, by using a chimerical soluble TGF-β type II receptor, induced a marked increase in the ischemic lesion that follows the transient occlusion of the middle cerebral artery in rats (Ruocco et al., 1999). Modulation of the expression of genes such as Notch-3 or Delta-1 is also of considerable interest in neuropathologic processes. The fate of neurons is thought to be determined by a series of local cell-cell interactions. Many reports would suggest that Notch-mediated intercellular signaling is involved in the events that control the spatial and temporal aspects of cell-fate determination (Weinmaster, 1997; Artavanis-Tsakonas et al., 1999; Perron and Harris, 2000; Selkoe, 2000). The modulation or dysfunction of such mechanisms may lead to severe brain disorders such as CADASIL (Joutel et al., 1996). Although these mechanisms need to be further clarified, our study suggests that cytokines, such as TGF-β1, may influence such processes. Similar comments can be made concerning the overexpression of cathepsin B. Although its mechanisms of action remain largely unknown, the expression of cathepsin B, which is largely confined to endosomes or lysosomes of neuronal cells (Cataldo et al., 1997), has been associated with amyloid-β accumulation (Frautschy et al., 1998) and neuronal cell shrinkage following transient cerebral ischemia (Hill et al., 1997). Furthermore, cathepsin B released by activated microglial cells have been shown to trigger apoptosis in primary neuronal cultures (Kingham and Pocok, 2001). Since cathepsin B expression is upregulated in brains of patients with Alzheimer disease, this may have significance for tissue damage and neuronal loss in the neuropathology of Alzheimer disease.

Of the genes that we have analyzed by RT-PCR, only two are modulated by TGF-β1 in cultured neurons. These observations suggest that astrocytes could be the major target for the responses to TGF-β1 in brain tissue. Altogether, these data may be related to studies that have described elevated concentrations of TGF-β1 in brain from patients with Parkinson disease (Lippa et al., 1995; Nagatsu et al., 2000), Alzheimer disease (van der Wal et al., 1993; Flanders et al., 1995), and stroke (Krupinski et al., 1996). Although it is necessary to be circumspect with such data, the use of a cDNA array appears to be a potent tool to identify novel targets for the understanding and eventual treatment of neurodegenerative conditions.

Footnotes

Abbreviations used

References

Artavanis-Tsakonas

Rand

M.D.

Lake

(1999) Notch signaling: cell fate control and signal integration in development. Science 284:770–776.

Boldin

M.P.

Goncharov

T.M.

Goltsev

Y.V.

Wallach

(1996) Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85:803–815.

Brodin

Ahgren

Ten Dijke

Heldin

C.H.

Heucher

(2000) Efficient TGF-β induction of the Smad7 gene requires cooperation between AP-1, Sp1, and Smad proteins on the mouse Smad7 promoter. J Biol Chem 275:29023–29030.

Buisson

Nicole

Docagne

Sartelet

MacKenzie

E.T.

Vivien

(1998) Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor beta1. FASEB J 12:1683–1691.

Cataldo

A.M.

Barnett

J.L.

Pieroni

Nixon

R.A.

(1997) Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J Neurosci 17:6142–6151.

Datta

P.K.

Blake

M.C.

Moses

H.L.

(2000) Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-β–induced physical and functional interactions between smads and Sp1. J Biol Chem 275:40014–40019.

Datto

M.B.

P.P.

Kowalik

T.F.

Yingling

Wang

X.F.

(1997) The viral oncoprotein E1A blocks transforming growth factor β-mediated induction of p21/WAF1/Cip1 and p15/INK4B. Mol Cell Biol 17:2030–2037.

Decraene

Reguigne-Arnould

Auffray

Piétu

(1999) Reverse transcription in the presence of dideoxynucleotides to increase the sensitivity of expression monitoring with cDNA arrays. Biotechniques 27:962–966.

Del Zoppo

G.J.

Wagner

Tagaya

(1997) Trends and future developments in the pharmacological treatment of acute ischemic stroke. Drugs 54:9–38.

10.

Dennler

Itoh

Vivien

Ten Dijke

Huet

Gauthier

J.M.

(1998) Direct binding of Smad3 and Smad4 to critical TGF β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17:3091–3100.

11.

Docagne

Nicole

Marti

H.H.

MacKenzie

E.T.

Buisson

Vivien

(1999) Transforming growth factor-β1 as a regulator of the serpins/t-PA axis in cerebral ischemia. FASEB J 13:1315–1324.

12.

Elbendary

Berchuck

Davis

Havrilesky

Bast

R.C.

Jr Iglehart

J.D.

Marks

J.R.

(1994) Transforming growth factor β1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ 5:1301–1307.

13.

Feng

X.H.

Lin

Derynck

(2000) Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-β. EMBO J 19:5178–5193.

14.

Flanders

K.C.

Lippa

C.F.

Smith

T.W.

Pollen

D.A.

Sporn

M.B.

(1995) Altered expression of transforming growth factor-β in Alzheimer's disease. Neurology 45:1561–1569.

15.

Flanders

K.C.

Ren

R.F.

Lippa

C.F.

(1998) Transforming growth factor-betas in neurodegenerative disease. Prog Neurobiol 54:71–85.

16.

Frautschy

S.A.

Horn

D.L.

Sigel

J.J.

Harris-White

M.E.

Mendoza

J.J.

Yang

Saido

T.C.

Cole

G.M.

(1998) Protease inhibitor coinfusion with amyloid β-protein results in enhanced deposition and toxicity in rat brain. J Neurosci 18:8311–8321.

17.

Hill

I.E.

Preston

Monette

MacManus

J.P.

(1997) A comparison of cathepsin B processing and distribution during neuronal death in rats following global ischemia or decapitation necrosis. Brain Res 751:206–216.

18.

Houlgatte

Mariage-Samson

Duprat

Tessier

Bentolila

Lamy

Auffray

(1995) The Genexpress Index: a resource for gene discovery and the genic map of the human genome. Genome Res 5:272–304.

19.

Hughes

R.E.

Olson

J.M.

(2001) Therapeutic opportunities in polyglutamine disease. Nat Med 7:419–423.

20.

Ignotz

R.A.

Endo

Massagué

(1987) Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-β. J Biol Chem 262:6443–6446.

21.

Inagaki

Truter

Ramirez

(1994) Transforming growth factor-β stimulates α2(I) collagen gene expression through a cis-acting element that contains an Sp1-binding site. J Biol Chem 269:14828–14834.

22.

Joutel

Corpechot

Ducros

Vahedi

Chabriat

Mouton

Alamowitch

Domenga

Cecillion

Marechal

Maciazek

Vayssiere

Cruaud

Cabanis

E.A.

Ruchoux

M.M.

Weissenbach

Bach

J.F.

Bousser

M.G.

Tournier-Lasserve

(1996) Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383:707–710.

23.

Keeton

M.R.

Curriden

S.A.

Van Zonneveld

A.J.

Loskutoff

D.J.

(1991) Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor β. J Biol Chem 266:23048–23052.

24.

Kim

S.J.

Jeang

K.T.

Glick

A.B.

Sporn

M.B.

Roberts

A.B.

(1989) Promoter sequences of the human transforming growth factor-β1 gene responsive to transforming growth factor-β1 autoinduction. J Biol Chem 264:7041–7045.

25.

Kingham

P.J.

Pocock

J.M.

(2001) Microglial secreted cathepsin B induces neuronal apoptosis. J Neurochem 76:1475–1484.

26.

Krieglstein

(1997) Transforming growth factor-β signaling and neuroprotection: relevance to ischemic brain injury, Alzheimer's, and Parkinson's disease. In: Neuroprotective signal transduction ( Mattson

, ed), Totowa, NJ: Humana Press, pp 119–144.

27.

Krupinski

Kumar

Kaluza

(1996) Increased expression of TGF-β1 in brain tissue after ischemic stroke in humans. Stroke 27:852–857.

28.

Lehrmann

Kiefer

Finsen

Diemer

N.H.

Zimmer

Hartung

H.P.

(1995) Cytokines in cerebral ischemia: expression of transforming growth factor β1 (TGF-β1) mRNA in the postischemic adult rat hippocampus. Exp Neurol 131:114–123.

29.

J.M.

Nichols

M.A.

Chandrasekharan

Xiong

Wang

X.F.

(1995) Transforming growth factor β activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site. J Biol Chem 270:26750–26753.

30.

Liberati

N.T.

Datto

M.B.

Frederick

J.P.

Shen

Wong

Rougier-Chapman

E.M.

Wang

X.F.

(1999) Smads bind directly to the Jun family of AP-1 transcription factors. Proc Natl Acad Sci USA 96:4844–4849.

31.

Lippa

C.F.

Smith

T.W.

Flanders

K.C.

(1995) Transforming growth factor-β: neuronal and glial expression in CNS degenerative diseases. Neurodegeneration 4:425–432.

32.

Martin-Villalba

Herr

Jeremias

Hahne

Brandt

Vogel

Schenkel

Herdegen

Debatin

K.M.

(1999) CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci 19:3809–3817.

33.

Massagué

(2000) How cells read TGF-β signals. Nat Rev Mol Cell Biol 1:169–178.

34.

Massagué

Wotton

(2000) Transcriptional control by the TGF-β/Smad signaling system. EMBO J 19:1745–1754.

35.

Matrisian

L.M.

Hogan

B.L.

(1990) Growth factor-regulated proteases and extracellular matrix remodeling during mammalian development. Curr Top Dev Biol 24:219–259.

36.

Matsuyama

Hata

Tagaya

Yamamoto

Nakajima

Furuyama

Wanaka

Sugita

(1994) Fas antigen mRNA induction in postischemic murine brain. Brain Res 657:342–346.

37.

Matsuyama

Hata

Yamamoto

Tagaya

Akita

Uno

Wanaka

Furuyama

Sugita

(1995) Localization of Fas antigen mRNA induced in postischemic murine forebrain by in situ hybridization. Brain Res Mol Brain Res 34:166–172.

38.

Mattson

M.P.

(2000) Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1:120–129.

39.

McCaffrey

T.A.

(2000) TGF-βs and TGF-β receptors in atherosclerosis. Cytokine Growth Factor Rev 11:103–114.

40.

Moustakas

Kardassis

(1998) Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc Natl Acad Sci USA 95:6733–6738.

41.

Muzio

Chinnaiyan

A.M.

Kischkel

F.C.

O'Rourke

Shevchenko

Scaffidi

Bretz

J.D.

Zhang

Gentz

Mann

Krammer

P.H.

Peter

M.E.

Dixit

V.M.

(1996) FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85:817–827.

42.

Muzio

Stockwell

B.R.

Stennicke

H.R.

Salvesen

G.S.

Dixit

D.M.

(1998) An induced proximity model for caspase-8 activation. J Biol Chem 273:2926–2930.

43.

Nagatsu

Mogi

Ichinose

Togari

(2000) Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 60:277–290.

44.

Pardali

Kurisaki

Moren

Ten Dijke

Kardassis

Moustakas

(2000) Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem 275:29244–29256.

45.

Perron

Harris

W.A.

(2000) Determination of vertebrate retinal progenitor cell fate by the Notch pathway and basic helix-loop-helix transcription factors. Cell Mol Life Sci 57:215–223.

46.

Peter

M.E.

Krammer

P.H.

(1998) Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol 10:545–551.

47.

Piek

Heldin

C.H.

Ten Dijke

(1999) Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J 13:2105–2124.

48.

Piétu

Alibert

Guichard

Lamy

Bois

Leroy

Mariage-Samson

Houlgatte

Soularue

Auffray

(1996) Novel gene transcripts preferentially expressed in human muscles revealed by quantitative hybridization of a high density cDNA array. Genome Res 6:492–503.

49.

Pinkoski

M.J.

Green

D.R.

(1999) Fas ligand, death gene. Cell Death Differ 6:1174–1181.

50.

Riccio

Pedone

P.V.

Lund

L.R.

Olensen

Olsen

H.S.

Andreasen

P.A.

(1992) Transforming growth factor β1-responsive element: closely associated binding sites for USF and CCAAT-binding transcription factor-nuclear factor I in the type 1 plasminogen activator inhibitor gene. Mol Cell Biol 12:1846–1855.

51.

Rose

Goldberg

M.P.

Choi

D.W.

(1993) In vitro biological methods. In: Methods in toxicology ( Tyson

C.A.

Frazier

J.M.

, eds) San Diego, CA: Academic Press, pp 46–60.

52.

Rosenbaum

D.M.

Gupta

D'Amore

Singh

Weidenheim

Zhang

Kessler

J.A.

(2000) Fas (CD95/APO-1) plays a role in the pathophysiology of focal cerebral ischemia. J Neurosci Res 61:686–692.

53.

Ruocco

Nicole

Docagne

Ali

Chazalviel

Komesli

Yablonsky

Roussel

MacKenzie

E.T.

Vivien

Buisson

(1999) A transforming growth factor-β antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury. J Cereb Blood Flow Metab 19:1345–1353.

54.

Schneider

Tschopp

(2000) Apoptosis induced by death receptors. Pharm Acta Helv 74:281–286.

55.

Selkoe

D.J.

(2000) Notch and presenilins in vertebrates and invertebrates: implications for neuronal development and degeneration. Curr Opin Neurobiol 10:50–57.

56.

Soares

M.B.

Bonaldo

M.F.

Jelene

Lawton

Efstratiadis

(1994) Construction and characterization of a normalized cDNA library. Proc Natl Acad Sci USA 91:9228–9232.

57.

Stennicke

H.R.

Jurgensmeier

J.M.

Shin

Deveraux

Wolf

B.B.

Yang

Zhou

Ellerby

H.M.

Ellerby

L.M.

Bredesen

Green

D.R.

Reed

J.C.

Froelich

C.J.

Salvesen

G.S.

(1998) Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem 273:27084–27090.

58.

Van der Wal

E.A.

Gomez-Pinilla

Cotman

C.W.

(1993) Transforming growth factor-β1 is in plaques in Alzheimer and Down pathologies. Neuroreport 4:69–72.

59.

Van Obberghen-Schilling

Roche

N.S.

Flanders

K.C.

Sporn

M.B.

Roberts

A.B.

(1988) Transforming growth factor β1 positively regulates its own expression in normal and transformed cells. J Biol Chem 263:7741–7746.

60.

Vivien

Buisson

(2000) Serine protease inhibitors: novel therapeutic targets for stroke? J Cereb Blood Flow Metab 20:755–764.

61.

Weinmaster

(1997) The ins and outs of notch signaling. Mol Cell Neurosci 9:91–102.

62.

Westerhausen

D.R.

Hopkins

W.E.

Billadello

J.J.

(1991) Multiple transforming growth factor-β-inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells. J Biol Chem 266:1092–1100.

63.

Wiessner

Gehrmann

Lindholm

Topper

Kreutzberg

G.W.

Hossmann

K.A.

(1993) Expression of transforming growth factor-P1 and interleukin-1 β mRNA in rat brain following transient forebrain ischemia. Acta Neuropathol (Berl) 86:439–446.

64.

Wong

Rougier-Chapman

E.M.

Frederick

J.P.

Datto

M.B.

Liberati

N.T.

J.M.

Wang

X.F.

(1999) Smad3-Smad4 and AP-1 complexes synergize in transcriptional activation of the c-Jun promoter by transforming growth factor β. Mol Cell Biol 19:1821–1830.

65.

Wyss-Coray

Feng

Masliah

Ruppe

M.D.

Lee

H.S.

Toggas

S.M.

Rockenstein

E.M.

Mucke

(1995) Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-β1. Am J Pathol 147:53–67.

66.

Wyss-Coray

Masliah

Mallory

McConlogue

Johnson-Wood

Lin

Mucke

(1997) Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease. Nature 389:603–606.

67.

Wyss-Coray

Lin

Yan

G.Q.

Rohde

McConlogue

Masliah

Mucke

(2001) TGF-β promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nat Med 7:612–618.

68.

Zhang

Feng

X.H.

Derynck

(1998) Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcription. Nature 394:909–913

Transforming Growth Factor-β1—Modulated Cerebral Gene Expression

Abstract

Keywords

MATERIALS AND METHODS

Cell cultures

Cortical cultures of astrocytes

Cultures of cortical neurons

Transgenic mice

Gene expression profiling

Human brain cDNA arrays

Preparation and labeling of complex cDNA targets

Hybridization and signal quantitation

Semiquantitative reverse transcriptase-polymerase chain reaction

RESULTS

Identification of brain-derived genes differentially expressed between wild-type and glial fibrillary acidic protein-transforming growth factor-β1 transgenic mice

Expression pattern of differentially expressed genes in cultured cortical neurons and astrocytes after exposure to transforming growth factor-β1

DISCUSSION

Footnotes

Abbreviations used

References